Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib

This study is measuring blood vessel function in patients with chronic myeloid leukemia (CML) — a blood cancer — who are being treated with targeted drugs called tyrosine kinase inhibitors (TKIs), specifically including a second-generation drug called bosutinib. Researchers want to understand how these medications affect the health of blood vessel walls over time. **You may be eligible if...** - You have been diagnosed with Philadelphia chromosome-positive CML in the chronic phase - You are currently taking a first- or second-generation TKI (imatinib, nilotinib, or bosutinib) - You have provided informed consent **You may NOT be eligible if...** - You have had a stroke or heart attack in the past - You have diabetes (type 1 or 2), chronic kidney disease, significant coronary artery disease, or severe high blood pressure - You have an irregular heartbeat (atrial fibrillation) or peripheral artery disease - You have another active cancer - Your cancer has developed resistance to TKI drugs Talk to your doctor to see if this trial is right for you.